Search

Your search keyword '"Eli Lilly and Co."' showing total 82,112 results
Start Over "Eli Lilly and Co."

Refine your results

more »

more »

more »

more »

more »

more »

more »

more »
82,112 results on '"Eli Lilly and Co."'

1. Event Brief of Q3 2024 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Evaluation, Eli Lilly and Co., Lilly Research Laboratories, Chairpersons, Pharmaceutical industry, Business, Verzenio (Medication) -- Evaluation, Mounjaro (Medication) -- Evaluation, Zepbound (Medication) -- Evaluation
Abstract

CORPORATE PARTICIPANTS . Joe Fletcher - Eli Lilly and Co,Senior Vice President of Investor Relations . David Ricks - Eli Lilly and Co,Chairman of the Board, President, Chief Executive Officer [...]

Published
2024

2. Q3 2024 Eli Lilly and Co Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Officials and employees, Eli Lilly and Co. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Business, Ebglyss (Medication) -- Evaluation, Verzenio (Medication) -- Evaluation, Mounjaro (Medication) -- Evaluation, Zepbound (Medication) -- Evaluation
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2024 earnings call. (Operator Instructions) I would now like to turn the conference over [...]

Published
2024

3. Eli Lilly and Co at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Business, Verzenio (Medication)
Abstract

Presentation TERENCE FLYNN, ANALYST, MORGAN STANLEY: Good morning everybody. Thanks for joining us. I'm Terence Flynn, the US biopharma analyst here at Morgan Stanley. Very pleased to be hosting Eli [...]

Published
2024

4. Event Brief of Eli Lilly and Co at TD Cowen Health Care Conference - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Health care industry, Business, Mounjaro (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Executive VP & CFO . Andrew Adams - Eli Lilly and Company,VP of New Therapeutic Modalities & Scientific Leader OVERVIEW Company [...]

Published
2024

5. Eli Lilly and Co at TD Cowen Health Care Conference - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Health care industry, Business, Mounjaro (Medication)
Abstract

Presentation ANAT ASHKENAZI, EXECUTIVE VP & CFO, ELI LILLY AND COMPANY: Thank you all for coming to listen to the Lilly story this morning, and hope I'm sure you've been [...]

Published
2024

6. Top 5 Trending Stocks Today: Eli Lilly and Co, Domino's Pizza, and Tesla

Subjects
Tesla Inc. -- Rankings, Palantir Technologies Inc. -- Rankings, Netflix Inc. -- Rankings, Domino's Pizza Inc. -- Rankings, Eli Lilly and Co. -- Rankings, Computer software industry -- Rankings, Online information services -- Rankings, Automobile industry -- Rankings, Pizzerias -- Rankings, Online services -- Rankings, Stocks -- Rankings, Restaurant industry -- Rankings, Information services -- Rankings, Stock price indexes, Pharmaceutical industry -- Rankings, Online information service, Automobile Industry, General interest, News, opinion and commentary
Abstract

* Major U.S. stock indices down, with Dow Jones Industrial Average dropping nearly 1.3%, S&P 500 falling almost 0.8%, and Nasdaq decreasing 0.7%. * Palantir Technologies Inc. (PLTR) shares rose [...]

Published
2024

7. US Stock Market Analysis: Dow Turns Lower, Myomo Shares Jump - Eli Lilly and Co

Subjects
Eli Lilly and Co., Dow Jones & Company Inc., Stock markets, Stocks -- Prices and rates, Newspaper publishing, Pharmaceutical industry, Stock market, General interest, News, opinion and commentary
Abstract

* Dow Jones index fell 0.19% to 39,301.00, while the NASDAQ rose 0.21% to 18,390.4. The S&P 500 also fell, dropping 0.02% to 5,566.26. * Materials shares jumped by 0.4%, [...]

Published
2024

8. Event Brief of Eli Lilly and Co at JPMorgan Healthcare Conference - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Novo Nordisk A/S -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Health care industry, Business
Abstract

CORPORATE PARTICIPANTS . David A. Ricks - Eli Lilly and Company,Chairman, CEO & President CONFERENCE CALL PARTICIPANTS . Christopher Thomas Schott - JPMorgan Chase & Co, Research Division,Senior Analyst OVERVIEW [...]

Published
2024

9. Eli Lilly and Co at JPMorgan Healthcare Conference - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Novo Nordisk A/S -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Mounjaro (Medication)
Abstract

Presentation CHRISTOPHER THOMAS SCHOTT, SENIOR ANALYST, JPMORGAN CHASE & CO, RESEARCH DIVISION: Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat [...]

Published
2024

10. Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2024 Featuring Pfizer, Novartis, Sanofi, Regeneron, LEO, Eli Lilly and Co, AbbVie, GSK, Innovaderm Research, and Johnson & Johnson

Subjects
Johnson & Johnson -- Reports, Eli Lilly and Co. -- Reports, Sanofi S.A. -- Reports, Atopic dermatitis -- Reports, Eczema -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-May 8, 2024-: Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2024 Featuring Pfizer, Novartis, Sanofi, Regeneron, LEO, Eli Lilly and Co, AbbVie, GSK, Innovaderm Research, and Johnson & [...]

Published
2024

11. Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2024 Featuring Pfizer, Novartis, Sanofi, Regeneron, LEO, Eli Lilly and Co, AbbVie, GSK, Innovaderm Research, and Johnson & Johnson

Subjects
Johnson & Johnson -- Reports, Eli Lilly and Co. -- Reports, Sanofi S.A. -- Reports, Atopic dermatitis -- Reports, Eczema -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Reports, General interest, News, opinion and commentary
Abstract

DUBLIN: RESEARCH AND MARKETS has issued the following news release: The 'Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024' clinical trials has been added to ResearchAndMarkets.com's offering. The [...]

Published
2024

12. Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2024 Featuring Pfizer, Novartis, Sanofi, Regeneron, LEO, Eli Lilly and Co, AbbVie, GSK, Innovaderm Research, and Johnson & Johnson - ResearchAndMarkets.com

Subjects
Johnson & Johnson -- Reports, Eli Lilly and Co. -- Reports, Sanofi S.A. -- Reports, Atopic dermatitis -- Reports, Eczema -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Reports, Business, Business, international
Abstract

DUBLIN -- The 'Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024' clinical trials has been added to ResearchAndMarkets.com's offering. The clinical trial report provides top line data relating [...]

Published
2024

13. Eli Lilly and Co at Evercore ISI HealthCONx Conference - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Financial analysts -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Trulicity (Medication)
Abstract

Presentation UMER RAFFAT, SENIOR MD & SENIOR ANALYST OF EQUITY RESEARCH, EVERCORE ISI INSTITUTIONAL EQUITIES, RESEARCH DIVISION: (technical difficulty) for being here. Pleasure to have management team from Eli Lilly. [...]

Published
2023

14. Eli Lilly and Co at UBS BioPharma Conference - Final

Subjects
UBS Investment Bank -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Biological products industry -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Securities industry, Business, Mounjaro (Medication)
Abstract

Presentation TRUNG CHUONG HUYNH, ANALYST, UBS INVESTMENT BANK, RESEARCH DIVISION: Okay. We're at the hour now. My name is Trung Huynh. I'm the U.S. pharma analyst here at UBS. Thank [...]

Published
2023

15. Q3 2023 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2023 Earnings Call. (Operator Instructions) I would now like to turn the conference over [...]

Published
2023

16. Event Brief of Q3 2023 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Lilly Research Laboratories -- Conferences, meetings and seminars, Patient compliance -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Jardiance (Medication), Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Executive VP & CFO . Anne E. White - Eli Lilly and Company,EVP & President of Lilly Neuroscience . Daniel M. [...]

Published
2023

17. Eli Lilly and Co at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Securities industry, Business
Abstract

Presentation TERENCE C. FLYNN, EQUITY ANALYST, MORGAN STANLEY, RESEARCH DIVISION: Okay. Great. I think we're going to get started. Thanks for joining us this afternoon. I'm Terence Flynn, the U.S. [...]

Published
2023

18. Eli Lilly And Co clocks 28% YoY revenue growth in Q4

Subjects
Eli Lilly and Co. -- Company sales and earnings, Diabetes therapy, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Mounjaro (Medication)
Abstract

Tuesday, Eli Lilly And Co LLY reported fourth-quarter of 2023 revenue of $9.35 billion, up 28% Y/Y, beating the consensus estimate of $8.93 billion on a 16% increase on higher [...]

Published
2024

19. Global Incretin Based Drugs Market Report 2023-2029 with Analysis of Leading Market Players like Eli Lilly and Co, Boehringer Ingelheim, Novo Nordisk, and AstraZeneca Among Others

Subjects
Boehringer Ingelheim GmbH -- Forecasts and trends, AstraZeneca PLC -- Forecasts and trends, Novo Nordisk A/S -- Forecasts and trends, Eli Lilly and Co. -- Forecasts and trends, Diabetes therapy -- Forecasts and trends, Type 2 diabetes -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Glucagon -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - The 'Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: [...]

Published
2024

20. Global Antibody Therapeutic Market Research Report 2024-2033 Featuring Key Players - AbbVie, Amgen, Johnson & Johnson Services, Eli Lilly and Co, and Hoffmann-La Roche

Subjects
Eli Lilly and Co. -- Forecasts and trends -- Market research, Viral antibodies -- Health aspects -- Reports -- Forecasts and trends, Marketing research -- Forecasts and trends -- Health aspects -- Reports, Antibodies -- Health aspects -- Reports -- Forecasts and trends, Pharmaceutical industry -- Market research -- Forecasts and trends, Marketing research, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - The 'Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033' report has been added [...]

Published
2024

21. Event Brief of Eli Lilly and Co at Goldman Sachs Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Executive VP & CFO CONFERENCE CALL PARTICIPANTS . Chris Shibutani - Goldman Sachs Group, Inc., Research Division,Research Analyst OVERVIEW None FINANCIAL [...]

Published
2023

22. Eli Lilly and Co at Goldman Sachs Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business
Abstract

Presentation CHRIS SHIBUTANI, RESEARCH ANALYST, GOLDMAN SACHS GROUP, INC., RESEARCH DIVISION: Okay. Let's kick off the afternoon session here. I hope everyone enjoyed the lunchtime discussion and has had a [...]

Published
2023

23. Global Insulin Pen Market Report 2024-2032 with Focus on China Featuring B. Braun Melsungen, Eli Lilly and Co, Becton, Dickinson, Novo Nordisk, Ypsomed, Terumo, Sanofi, Julphar

Subjects
Injections -- Market research, Medical test kit industry -- Market research, Medical equipment and supplies industry -- Market research, Marketing research, Business, Business, international
Abstract

M2 PRESSWIRE-July 23, 2024-: Global Insulin Pen Market Report 2024-2032 with Focus on China Featuring B. Braun Melsungen, Eli Lilly and Co, Becton, Dickinson, Novo Nordisk, Ypsomed, Terumo, Sanofi, Julphar [...]

Published
2024

24. Premature Ejaculation Treatment Business Research Report 2024 Featuring Absorption Pharma, Allergan, AstraZeneca, Bayer, Eli Lilly and Co, GSK, Innovus, Merck, Pfizer, and Teva

Subjects
Business -- Research, Premature ejaculation -- Forecasts and trends -- Reports, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

Dublin: Research and Markets has issued the following press release: The 'Premature Ejaculation Treatment - Global Strategic Business Report' report has been added to ResearchAndMarkets.com's offering. The global market for [...]

Published
2024

25. Biopharmaceuticals Global Business Report 2024 with Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli Lilly and Co, F. Hoffmann-La Roche, J&J, Merck, Novo Nordisk, Pfizer, Sanofi

Subjects
Biological products industry -- Forecasts and trends, Biopharmaceutics -- Reports -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

Dublin: Research and Markets has issued the following news release: The 'Biopharmaceuticals - Global Strategic Business Report' report has been added to ResearchAndMarkets.com's offering. The global market for Biopharmaceuticals is [...]

Published
2024

26. United States Pain Management Therapeutics Market Research 2024-2032 Featuring Eli Lilly and Co, Pfizer,. GSK,c Novartis, Merck & Co, Abbott Laboratories, Johnson & Johnson, & Baxter

Subjects
Marketing research, Pain -- Care and treatment, Analgesics -- Market research, Marketing research, Company business management, General interest, News, opinion and commentary
Abstract

Dublin: Research and Markets has issued the following news release: The 'United States Pain Management Therapeutics Market and Forecast Therapeutics (Devices and Pharmaceuticals), Pain Type, Drug Class, Indication, Distribution Channel [...]

Published
2024

27. Eli Lilly and Co at Bank of America Global Healthcare Conference - Final

Subjects
Bank of America Corp. -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Financial analysts -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Banking industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Banking industry, Business, Olumiant (Medication), Mounjaro (Medication)
Abstract

Presentation GEOFFREY CHRISTOPHER MEACHAM, RESEARCH ANALYST, BOFA SECURITIES, RESEARCH DIVISION: Okay. Welcome to the second day of the BofA Healthcare Conference. My name is Geoff Meacham, and I'm the senior [...]

Published
2023

28. Eli Lilly and Co at Cowen Health Care Conference - Final

Subjects
Eli Lilly and Co., Obesity, Health care industry, Conferences and conventions, Type 2 diabetes, Pharmaceutical industry, Health care industry, Business, Trulicity (Medication), Mounjaro (Medication)
Abstract

Presentation UNIDENTIFIED ANALYST: At the Cowen conference again this year. Representing the company is Mike Mason, who is President of Lilly Diabetes. So Mike, thank you for making the journey. [...]

Published
2023

29. Eli Lilly And Co put volume heavy and directionally bearish

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Bearish flow noted in Eli Lilly And Co with 5,552 puts trading, or 1.5x expected. Most active are Nov-22 310 puts and Oct-22 200 puts, with total volume in those [...]

Published
2022

30. United States Pain Management Therapeutics Market Report 2023: A $33.71 Billion Market by 2030 with Eli Lilly and Co, Pfizer, GSK, Novartis, Merck, Abbott Laboratories, J&J, and Baxter Dominating

Subjects
Eli Lilly and Co. -- Forecasts and trends -- Management, Abbott Laboratories (Abbott Park, Illinois) -- Forecasts and trends -- Management, Pain -- Care and treatment, Pharmaceutical industry -- Statistics -- Forecasts and trends, Company business management, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'United States Pain Management Therapeutics Market, Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis' report has [...]

Published
2023

31. United States Pain Management Therapeutics Market Report 2023: A $33.71 Billion Market by 2030 with Eli Lilly and Co, Pfizer, GSK, Novartis, Merck, Abbott Laboratories, J&J, and Baxter Dominating

Subjects
Eli Lilly and Co. -- Management -- Statistics, Abbott Laboratories (Abbott Park, Illinois) -- Management -- Statistics, Pain -- Care and treatment, Pharmaceutical industry -- Statistics, Company business management, Business, News, opinion and commentary
Abstract

DUBLIN, Nov. 14, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5562701/united-states-pain-management-therapeutics?utm_source=CI&utm_medium=PressRelease&utm_code=ffpgmn&utm_campaign=1908974+-+United+States+Pain+Management+Therapeutics+Market+Report+2023%3a+A+%2433.71+Billion+Market+by+2030+with+Eli+Lilly+and+Co%2c+Pfizer%2c+GSK%2c+Novartis%2c+Merck%2c+Abbott+Laboratories%2c+J%26J%2c+and+Baxter+Dominating&utm_exec=chdo54prd report has been added toResearchAndMarkets.com's offering. United States Pain Management Therapeutics Market is expected to reach US$ 33.71 Billion by 2030 from [...]

Published
2023

32. Thinking about trading options or stock in Palantir Technologies, Broadcom, Eli Lilly And Co, General Electric, or Taiwan Semiconductor?

Subjects
Palantir Technologies Inc., Eli Lilly and Co., General Electric Co., Options (Finance), Computer software industry, Electrical equipment and supplies industry, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

NEW YORK: InvestorsObserver has issued the following news release: InvestorsObserver issues critical PriceWatch Alerts for PLTR, AVGO, LLY, GE, and TSM. InvestorsObserver provides patented technology to some of the biggest [...]

Published
2023

33. Eli Lilly and Co at SVB Securities Global Biopharma Conference (Virtual) - Final

Subjects
Eli Lilly and Co., Biological products industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Mounjaro (Medication)
Abstract

Presentation DAVID REED RISINGER, SENIOR MD, SVB SECURITIES LLC, RESEARCH DIVISION: Great. Good morning, everybody. So thanks very much for joining us for this next session with Eli Lilly. On [...]

Published
2023

34. Eli Lilly and Co at Guggenheim Healthcare Talks Oncology Day - Final

Subjects
Eli Lilly and Co., Loxo Oncology Inc., Health care industry, Pharmaceutical industry, Health care industry, Business, Verzenio (Medication)
Abstract

Presentation SEAMUS CHRISTOPHER FERNANDEZ, SENIOR ANALYST OF GLOBAL PHARMACEUTICALS, GUGGENHEIM SECURITIES, LLC, RESEARCH DIVISION: All right. Thanks, everybody. I'm Seamus Fernandez, the global biopharma analyst here at Guggenheim Securities. This [...]

Published
2023

35. Eli Lilly and Co at JPMorgan Healthcare Conference - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Health care industry, Business, Trulicity (Medication), Mounjaro (Medication)
Abstract

Presentation CHRISTOPHER THOMAS SCHOTT, SENIOR ANALYST, JPMORGAN CHASE & CO, RESEARCH DIVISION: Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat [...]

Published
2023

36. Event Brief of Eli Lilly and Co Guidance Call 2023 - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Type 2 diabetes -- Conferences, meetings and seminars, Business, Trulicity (Medication), Mounjaro (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Neuroscience . Daniel [...]

Published
2022

37. Eli Lilly and Co Guidance Call 2023 - Final

Subjects
Pfizer Inc., Eli Lilly and Co., Type 2 diabetes, Business, Trulicity (Medication), Mounjaro (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly 2023 Guidance Conference Call. (Operator Instructions) And as a reminder, this conference is being recorded. [...]

Published
2022

38. Regulatory update: United States Nuclear Regulatory Commission has submitted (Haldeman K M ) 30 Day Report for Eli Lilly and Co. Lost Tritium Exit Sign, EN57025, NMED 240100

Subjects
United States. Nuclear Regulatory Commission, Independent regulatory commissions, News, opinion and commentary
Abstract

Washington: United States Nuclear Regulatory Commission has issued the following document: April 4, 2024 United States Nuclear Regulatory Commission, Region III Attn: Regional Administrator 2443 Warrenville Road, Suite 210 Lisle, [...]

Published
2024

39. Eli Lilly and Co at Evercore ISI HealthCONx Conference (Virtual) - Final

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Loxo Oncology Inc. -- Conferences, meetings and seminars, Financial analysts -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Presentation UMER RAFFAT, SENIOR MD & SENIOR ANALYST OF EQUITY RESEARCH, EVERCORE ISI INSTITUTIONAL EQUITIES, RESEARCH DIVISION: Thank you, guys, for joining us. It's a pleasure to have Eli Lilly [...]

Published
2022

40. Event Brief of Q3 2022 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co. -- Officials and employees, Pharmaceutical industry -- Officials and employees, Business, Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

CORPORATE PARTICIPANTS . Anat Ashkenazi - Eli Lilly and Company,Senior VP & CFO . Anne E. White - Eli Lilly and Company,Senior VP & President of Lilly Neuroscience . Daniel [...]

Published
2022

41. Q3 2022 Eli Lilly and Co Earnings Call - Final

Subjects
Eli Lilly and Co., Pharmaceutical industry, Business, Trulicity (Medication), Verzenio (Medication), Mounjaro (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2022 Earnings Conference Call. (Operator Instructions) And as a reminder, your conference is being [...]

Published
2022

42. Eli Lilly and Co at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Business, Trulicity (Medication), Mounjaro (Medication), Taltz (Medication)
Abstract

Presentation TERENCE C. FLYNN, EQUITY ANALYST, MORGAN STANLEY, RESEARCH DIVISION: Great. Well, thanks, everybody, for joining us. I'm Terence Flynn, the U.S. pharma analyst here at Morgan Stanley. We're very [...]

Published
2022

43. Eli Lilly and Co at Citi BioPharma Conference - Final

Subjects
Citigroup Inc. -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Biological products industry -- Conferences, meetings and seminars, Financial services industry -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Financial services industry, Business
Abstract

Presentation ANDREW SIMON BAUM, GLOBAL HEAD OF HEALTHCARE RESEARCH AND MD, CITIGROUP INC., RESEARCH DIVISION: So good afternoon. Welcome back. Delighted to introduce our session. We have from Lilly, Dan [...]

Published
2022

44. Eli Lilly and Co at Goldman Sachs Global Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business
Abstract

Presentation CHRIS SHIBUTANI, RESEARCH ANALYST, GOLDMAN SACHS GROUP, INC., RESEARCH DIVISION: Okay. We're good. Thank you very much everybody, and welcome to this Tuesday session at the Goldman Sachs Healthcare [...]

Published
2022

45. Eli Lilly and Co Diabetes & Obesity Update at ADA Call - Final

Subjects
Eli Lilly and Co., Obesity, Type 2 diabetes, Pharmaceutical industry, Business, Trulicity (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Welcome to the ADA Investor Update. (Operator Instructions) As a reminder, today's conference is being recorded. And I would now [...]

Published
2022

46. Global Insulin Pens Market Forecast to 2033: Players Include Novo Nordisk AS, Eli Lilly and Co and Sanofi

Subjects
Novo Nordisk A/S -- Reports, Eli Lilly and Co. -- Reports, Sanofi S.A. -- Reports, Diabetes therapy -- Reports, Insulin -- Reports, General interest, News, opinion and commentary
Abstract

Dublin: Research and Markets has issued the following news release: The 'Insulin Pens Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures [...]

Published
2023

47. Global Premature Ejaculation Therapeutics Market Insights Report 2024-2029 Featuring Prominent Vendors - Plethora Solutions, Pfizer, Eli Lilly and Co, GSK, Menarini

Subjects
Pfizer Inc. -- Forecasts and trends, Premature ejaculation -- Forecasts and trends -- Reports, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-December 8, 2023-: Global Premature Ejaculation Therapeutics Market Insights Report 2024-2029 Featuring Prominent Vendors - Plethora Solutions, Pfizer, Eli Lilly and Co, GSK, Menarini (C)1994-2023 M2 COMMUNICATIONS RDATE:08122023 The [...]

Published
2023

48. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Analysis Report 2024: A $133.5 Billion in 2030 Featuring Eli Lilly and Co, Pfizer, Sanofi, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk

Subjects
Distribution channels -- Forecasts and trends -- Reports -- Statistics, Patient compliance -- Statistics -- Forecasts and trends -- Reports, Type 2 diabetes -- Forecasts and trends -- Statistics -- Reports, Direct market channel, Retail/reseller channel, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Global Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type, End-Use (Type 2 Diabetes, NASH, Obesity), By [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results